Establishment and characterization of CHC-X1: the third human combined hepatocellular–cholangiocarcinoma cell line

Bibliographic Details
Title: Establishment and characterization of CHC-X1: the third human combined hepatocellular–cholangiocarcinoma cell line
Authors: Huan Tang, Changpeng Chai, Xin Miao, Yuanhui Su, Cheng Yu, Jianfeng Yi, Zhengfeng Wang, Hui Zhang, Zhenjie Zhao, Linpei Wang, Wence Zhou, Hao Xu
Source: BMC Cancer, Vol 25, Iss 1, Pp 1-14 (2025)
Publisher Information: BMC, 2025.
Publication Year: 2025
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Combined hepatocellular-cholangiocarcinoma, Cell lines, Transplanted tumor, Drug sensitivity, Drug resistance, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) represents an uncommon variant of primary liver cancer. In recent years, its incidence rate has increased. Thus, it is essential to perform comprehensive investigations into cHCC-CCA to develop suitable treatment strategies. So far, only two cell lines (CLs) of this cancer type have been reported. More cHCC-CCA CLs need to be established for research purposes. In this investigation, we developed a stable cHCC-CCA CL, named CHC-X1. STR analysis confirmed that CHC-X1 is a new human cHCC-CCA CL. CHC-X1 is a complex karyotype. Its population doubling time is 50.72 h. Under suspended conditions, CHC-X1 can form tumor spheres and organoids in Matrigel. These cells exhibit sensitivity to paclitaxel while demonstrating resistance against oxaliplatin, gemcitabine, and 5-FU. After inoculation into NXG mice, CHC-X1 can quickly form subcutaneous transplant tumors, exhibiting a tumor establishment rate of 67%. Immunohistochemical staining showed that CHC-X1 is a tumor CL with both liver cell differentiation and bile duct cell differentiation characteristics. It may function as a useful model for identifying the origins of cHCC-CCA and the advancement of potential treatments.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1471-2407
Relation: https://doaj.org/toc/1471-2407
DOI: 10.1186/s12885-025-13876-9
Access URL: https://doaj.org/article/64b42eb45fa54a7b8ccea6c7c00e9839
Accession Number: edsdoj.64b42eb45fa54a7b8ccea6c7c00e9839
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:14712407
DOI:10.1186/s12885-025-13876-9
Published in:BMC Cancer
Language:English